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Edited by Frances ShannonAbstract Utrophin is the autosomal homolog of dystrophin, the
product of the Duchenne’s muscular dystrophy (DMD) locus.
Utrophin is of therapeutic interest since its over-expression can
compensate dystrophin’s absence. Utrophin is enriched at neuro-
muscular junctions due to heregulin-mediated utrophin-A pro-
moter activation. We demonstrate that heregulin activated
MSK1/2 and phosphorylated histone H3 at serine 10 in cultured
C2C12 muscle cells, in an ERK-dependent manner. MSK1/2
inhibition suppressed heregulin-mediated utrophin-A activation.
MSK1 over-expression potentiated heregulin-mediated utro-
phin-A activation and chromatin remodeling at the utrophin-A
promoter. These results identify MSK1/2 as key eﬀectors modu-
lating utrophin-A expression as well as identify novel targets for
DMD therapy.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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DMD is the most common fatal X-linked disorder aﬀecting
1 in 3500 boys. The disease is caused by mutations in the DMD
gene, leading to defects in dystrophin expression [1,2].
Utrophin is the chromosome 6-encoded autosomal homolog
of dystrophin, and bears signiﬁcant structural and functional
similarities to dystrophin [3–5]. Utrophin is driven by two pro-
moters (A & B) and the restricted localization of utrophin-A
occurs in part due to selective expression of the utrophin-A
gene product in sub-synaptic nuclei [6,7]. Utrophin can
functionally substitute for missing dystrophin; upregulation
achieved by transgenic means [8,9], viral vectors [10] and
pharmacological approaches [11,12] ameliorate the dystrophic
phenotype of mdx mice [13].
Concerted eﬀorts have begun to identify the molecular
mechanisms regulating utrophin expression. We and others
have shown that heregulin (HRG) binding to cell surface*Corresponding author. Fax: +1 215 573 5851.
E-mail address: tsk@mail.med.upenn.edu (T.S. Khurana).
1Equal contributors.
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.07.021erbB/HER receptors leads to ERK-dependent phosphoryla-
tion of the ets-related GABPa/b transcription factor complex
which in turn leads to enhanced binding of the overlapping
ets/N-box site, activation of utrophin-A promoter and
increased transcription in cultured muscle [7,14], in a manner
similar to that described for acetylcholine receptors [15]. In
addition, cognate binding site mapping and activation by
other transcription factors (e.g. SP1, NFAT, PGC-1a) has
also been described [13,16,17]. However, transcriptional acti-
vation of genes also depends on remodeling of the chromatin
structure [18,19]. Nevertheless, the identity of intracellular
eﬀectors and chromatin-level changes that ultimately allow
increased utrophin-A promoter activation are yet to be de-
scribed. At periods of intense transcriptional activity phos-
phorylation at Ser10 and Ser28 of the core histone H3 has
been noted [19–21]. Notably, histone H3 Ser10 phosphoryla-
tion correlates well with the induction of immediate-early
genes as well as with other inducible genes [22]. The well-
established targets of ERK- and p38-type MAP kinases, the
mitogen- and stress-activated protein kinases-1 and -2
(MSK1/2) are histone H3 Ser10 and Ser28 kinases [21–24],
and thereby provide clues for potential downstream eﬀectors
for ERK-mediated activation of utrophin-A by heregulin.
Here, we identify and characterize MSK1/2 as eﬀectors of
heregulin-mediated chromatin remodeling at the utrophin-A
promoter.2. Results
2.1. Heregulin activates MSK
To address the possibility that the major growth factor-stim-
ulated histone H3 kinases MSK1/2 are downstream eﬀectors of
heregulin, we determined the levels of the active forms of
ERK, p38 and MSK1/2 in the C2C12 muscle cell line after
incubation with heregulin at diﬀerent time points (Fig. 1A).
Consistent with previous reports, heregulin treatment was
found to increase levels of active ERK1/2 and to a minor ex-
tent p38 (Fig. 1A). Ten minutes of heregulin treatment was suf-
ﬁcient to activate these kinases. Using phospho-speciﬁc
antibodies recognizing the essential, activating phosphoryl-
ation site serine 376 of MSK1/2, we observed that heregulin-
induced phosphorylation of MSK1/2 with a time course simi-
lar to that for activation of ERK (Fig. 1A). To independently
verify the results we assayed MSK1/2 kinase activity upon
heregulin stimulation. As can be seen in Fig. 1B, heregulinblished by Elsevier B.V. All rights reserved.
Fig. 1. Heregulin activates MSK1/2 in C2C12 cultured muscle cells.
Serum-starved C2C12 cells were treated with 2 nM heregulin for times
indicated and analyzed by Western blots. (A) Phospho ERK1/2, active
p38 and phospho MSK1/2 antibodies revealing increased phosphor-
ylation of ERK1/2 and MSK1/2 but only slightly increased phosphor-
ylation of p38. b-Actin was used as control for equal loading. Total
MSK1/2 enzymatic activity (B) measured from cell lysates in parallel
experiments shows maximal activation by heregulin at 10 0 (Bargraph:
0 0, 0.30 ± 0.61AU; 5 0, 0.81 ± 0.63AU; 10 0, 2.54 ± 1.02AU; 15 0,
1.86 ± 0.48AU; n = 4). Total MSK1/2 enzymatic activity assays (C)
show ERK-dependence. C2C12 cells were serum-starved overnight,
treated with or without MEK inhibitor, U0126 (10 lM) for 15 0 and
then were incubated with 2 nM heregulin for 10 0 (control
0.82 ± 0.62AU; HRG 3.67 ± 0.90AU; U0126 1.07 ± 0.65; U0126 +
HRG 1.8 ± 0.46AU; n = 4). **Statistical signiﬁcance P < .01.
Fig. 2. MSK1 plays a critical role in heregulin-induced utrophin-A
promoter activation. Schematic (A) of the utrophin-A promoter
luciferase construct was co-transfected into C2C12 cells along with
transfection control pRL-TK. C2C12 cells transfected with utrophin-A
promoter-reporter were serum-starved and (B) treated with 2 nM
heregulin and the MSK inhibitor (5 lM of GF109203X) for 30 0 as
indicated and showed signiﬁcant reduction of heregulin-induced
utrophin-A promoter activity in the presence of pharmacological
inhibition of MSK1/2 (Bargraph: control 100 ± 13.73; HRG
170.30 ± 24.22; control + GF109203X 104.2 ± 10.65; HRG +
GF109203X 137.3 ± 25.47; n = 5). These cells were also (C) transfected
with either the empty vector pMT or MSK1 expressing constructs
(pMSK1) prior to overnight serum starvation and heregulin-stimula-
tion and showed potentiation of heregulin-induced utrophin-A pro-
moter activity by MSK1. (Bargraph: pMT 100.0 ± 19.28;
pMT + HRG 227.10 ± 23.04; pMSK1 91.71 ± 17.41; pMSK1 + HRG
440.50 ± 51.65; n = 5). Schematic (D) of the N-box deleted utrophin-A
promoter luciferase construct co-transfected into C2C12 cells along
with pRL-TK. Cells were also (E) transfected with either empty vector
pMT or MSK1 constructs (pMSK1) prior to overnight serum
starvation and heregulin-stimulation. Neither heregulin nor MSK1
showed upregulation (Bargraph: pMT 100.9 ± 14.58; pMT + HRG
106.5 ± 1.686; pMSK1 102.7 ± 7.617; pMSK1 + HRG 93.27 ± 5.339;
n = 5). Luciferase activity is normalized to pRL-TK-derived luciferase
activity (internal control) and expressed as 100% in the control group.
**Statistical signiﬁcance P < .01.
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served at 10 min and the time course was similar to that noted
using phospho-speciﬁc antibodies against MSK1/2. To investi-
gate if ERK-dependence contributed to the tight temporal cor-
relation between heregulin-mediated activation of ERK1/2 and
MSK1/2, we pretreated C2C12 cells with U0126, a speciﬁc
inhibitor of MEK, the upstream kinase activating ERK.
Heregulin-stimulated activation of MSK1/2 was signiﬁcantly
suppressed in U0126 treated cells (Fig. 1C), demonstrating
that ERK plays a major role in heregulin-mediated MSK1/2
activation.
Fig. 3. MSK1 enhances endogenous utrophin expression upon hereg-
ulin-stimulation. C2C12 cells transfected with either empty vector,
pMT or MSK1 construct (pMSK1) were serum-starved overnight
followed by treatment with 2 nM heregulin (HRG) for 30 min. MSK1
overexpression showed potentiation of heregulin-mediated utrophin
(A) mRNA upregulation (Bargraph: pMT 0.9361 ± .040;
pMT + HRG 1.503 ± .085; pMSK1 1.018 ± 0.052; pMSK1 + HRG
2.168 ± 0.074; n = 4). In contrast, heregulin did not show any eﬀect on
myostatin (B) mRNA expression (Bargraph: pMT 1.044 ± 0.0.085;
pMT + HRG 0.9979 ± 0.139; pMSK1 1.139 ± 0.225; pMSK1 + HRG
1.035 ± 0.034; n = 4). The eﬀect of MSK1 overexpression on heregulin-
mediated utrophin upregulation was translated to protein level as
revealed by anti-utrophin Western blot (C). Tubulin was used as
loading control. The band intensities of Western blot experiment were
quantiﬁed and the ratio of utrophin and corresponding tubulin bands
were plotted (D). **Statistical signiﬁcance P < .05.
Fig. 4. Heregulin-induced chromatin remodeling at the utrophin-A
promoter. Serum-starved C2C12 cells were treated with 2 nM hereg-
ulin at time points indicated and analyzed by Western blots (A) using
phosphohistone H3(Ser10) antibody reveals increased phosphoryla-
tion. Anti-H3 antibody was used as control for equal loading. The
ratio of band intensities of phosphohistone and corresponding histone
showed extent of phosphorylation (B). Immunoﬂuorescence (C) using
these antibodies demonstrated increases in global phosphorylation of
histone H3 and increased punctate, speckling indicative of activation
of promoters. Scale bar = 25 lm. ChIP (D) was performed on serum
starved C2C12 cells that were transfected with MSK1 followed by
incubation with 2 nM heregulin. Lysates were analyzed using no
antibody (top lane) or phosphohistone H3(Ser10) antibody (middle
lane). Radioactive PCR using primers from the utrophin-A promoter
region revealed that heregulin-induces chromatin remodeling at the
utrophin-A promoter. Aliquots of inputs were used as control (lower
lane). The band intensities were quantiﬁed and the ratio of phospho-
histone and corresponding input band as the measure of occupancy of
phosphohistone H3 at utrophin promoter showed 1.4-fold increase
upon heregulin treatment (3E).
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activation
Having demonstrated that heregulin phosphorylates and
activates MSK1/2, we asked whether MSK1/2 plays a role in
heregulin-stimulated utrophin upregulation. Serum-starved
C2C12 cells were transfected with a full-length utrophin-A
promoter luciferase reporter construct (Fig. 2A) in the absence
or presence of the MSK1/2 inhibitor GF109203X followed by
heregulin-stimulation. As shown in Fig. 2B, heregulin-induced
utrophin-A promoter activation was suppressed by
GF109203X. To independently validate MSK1/2 as an intra-
cellular eﬀector of heregulin-mediated utrophin promoter acti-
vation, we co-transfected the utrophin promoter reporter
construct along with an expression construct for wild typeFig. 5. Transcriptional model of the utrophin-A promoter by heregulin
phosphorylated protein; dotted and full arrowed lines represent potential anMSK1 and stimulated with heregulin. While MSK1 overex-
pression alone did not change the basal level of utrophin pro-
moter activity per se, MSK1 overexpression potentiated the
heregulin-mediated activation of the utrophin promoter
(Fig. 2C). MSK1 overexpression did not show any eﬀect over
N-box deleted utrophin promoter (Fig. 2E), which is insensi-
tive to heregulin.
The role of MSK1 on utrophin promoter activation was fur-
ther conﬁrmed by the study of endogenous utrophin level
(Fig. 3). Taqman real time PCR (Fig. 3A) and Western blot
(Fig. 3C and D) showed that MSK1 potentiated the heregu-
lin-stimulated utrophin upregulation, while myostatin, a non-
synaptic gene remained insensitive (Fig. 3B).-stimulation. Multiple arrows represent increased transcription; P,
d deﬁned signaling cascades, respectively. See text for details.
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promoter
Since MSK1/2 are known histone H3 kinases, we reasoned
that heregulin-mediated activation of MSK1/2 might promote
histone H3 phosphorylation. To test this possibility, C2C12
cells were stimulated with heregulin for diﬀerent times and
the extent of total histone H3 phosphorylation was analyzed
by Western blotting and immunostaining using antibodies
that speciﬁcally recognize phosphorylation of histone H3
(Ser10). Western blotting showed that heregulin-stimulation
led to a small increase in histone H3 phosphorylation within
10 min (Fig. 4A and B). To determine if heregulin-mediated
increases in histone H3 (Ser10) phosphorylation occurred at
regions of active gene transcription, we ﬁrst examined nuclei
of non-mitotic, heregulin-treated cells by confocal microscopy
using antibodies recognizing the phosphohistone H3 (Ser10)
residue. Immunostaining revealed increased punctuate speck-
ling representative of localized histone H3 phosphorylation
thought to occur at MSK target genes [23] in heregulin-trea-
ted muscle cells (Fig. 4C). Next we asked whether heregulin
could induce histone H3 phosphorylation at the utrophin-A
promoter itself. Using anti-phosphohistone H3 (Ser10) anti-
bodies we performed chromatin immunoprecipitation (ChIP)
analysis of the utrophin-A promoter in C2C12 cells that had
been transfected with an expression construct for MSK1 and
treated with heregulin for 10 min or left untreated. Using
ChIP we detected 1.4-fold increased histone H3 (Ser 10)
phosphorylation at the utrophin-A promoter after heregu-
lin-stimulation (Fig. 4D and E). These data provide a mech-
anistic basis for heregulin-mediated increase in utrophin-A
promoter activity.3. Discussion
Our data provide a model (Fig. 5) for heregulin-mediated
upregulation of utrophin promoter-A in muscle. We propose
that binding of the neurite-associated growth factor heregulin
to cell surface erbB/HER receptors at the NMJ leads to recep-
tor activation by phosphorylation and activation of a variety
of intracellular signaling pathways such as ERK. This in turn
leads to ERK-dependent phosphorylation and activation of
MSK1/2 as well as phosphorylation of transcription factors
such as ets-related GABPa/b complex and SP1. Phosphoryla-
tion of these and other transcription factors (e.g. NFAT,
PGC-1a) in turn leads to recognition and enhanced binding
of these transcription factors to their respective binding sites
on the utrophin-A promoter, in some cases with synergistic
co-operability [13,17]. The recognition and recruitment of the
transcription factors to the promoter is accompanied by
MSK-mediated chromatin remodeling of the utrophin-A pro-
moter which in turn, facilitates transcription of the utrophin
gene.
In conclusion, we have identiﬁed a role for MSK1/2 as an
intracellular eﬀector of heregulin-mediated chromatin remod-
eling and activation of the utrophin-A promoter in muscle
cells. Modulating MSK1/2 or related histone kinases as well
as histone H3 phosphorylation and/or acetylation at the utro-
phin enhanceosome may provide a novel pharmacological
strategy to achieve utrophin upregulation in DMD patients.
In the hemoglobinopathies, some degree of success has alreadybeen achieved using drugs such as sodium butyrate to activate
fetal hemoglobin promoter in order to functionally substitute
for mutated adult haemoglobin [25]. Similar strategies may
be able to achieve therapeutic utrophin upregulation in
DMD skeletal muscle, however this hypothesis needs to be
tested in vivo.4. Material and methods
Note. Details provided as Supplementary data (S1).
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